Influence of Polymer Molecular Weight on Drug-Polymer Solubility: A Comparison between Experimentally Determined Solubility in PVP and Prediction Derived from Solubility in Monomer.

In this study, the influence of polymer molecular weight on drug-polymer solubility was investigated using binary systems containing indomethacin (IMC) and polyvinylpyrrolidone (PVP) of different molecular weights. The experimental solubility in PVP, measured using a differential scanning calorimetry annealing method, was compared with the solubility calculated from the solubility of the drug in the liquid analogue N-vinylpyrrolidone (NVP). The experimental solubility of IMC in the low-molecular-weight PVP K12 was not significantly different from that in the higher molecular weight PVPs (K25, K30, and K90). The calculated solubilities derived from the solubility in NVP (0.31-0.32 g/g) were found to be lower than those experimentally determined in PVP (0.38-0.40 g/g). Nevertheless, the similarity between the values indicates that the analogue solubility can provide valuable indications on the solubility in the polymer. Hence, if a drug is soluble in an analogue of the polymer, it is most likely also soluble in the polymer. In conclusion, the solubility of a given drug-polymer system is determined by the strength of the drug-polymer interactions rather than the molecular weight of the polymer. Therefore, during the first screenings for drug solubility in polymers, only one representative molecular weight per polymer is needed.

[1]  JULIAN F. Johnson,et al.  Influence of molecular weight and molecular weight distribution on mechanical properties of polymers , 1982 .

[2]  M. Descamps,et al.  A new protocol to determine the solubility of drugs into polymer matrixes. , 2013, Molecular pharmaceutics.

[3]  G. Van den Mooter,et al.  Review: physical chemistry of solid dispersions. , 2009, The Journal of pharmacy and pharmacology.

[4]  Ford Jl,et al.  The current status of solid dispersions. , 1986 .

[5]  Lian Yu,et al.  Solubility of Small-Molecule Crystals in Polymers: d-Mannitol in PVP, Indomethacin in PVP/VA, and Nifedipine in PVP/VA , 2009, Pharmaceutical Research.

[6]  Bradley D Anderson,et al.  Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions. , 2013, Journal of pharmaceutical sciences.

[7]  F. Haaf,et al.  Polymers of N-Vinylpyrrolidone: Synthesis, Characterization and Uses , 1985 .

[8]  Lynne S. Taylor,et al.  Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions , 1997, Pharmaceutical Research.

[9]  Raymond C Rowe,et al.  Handbook of Pharmaceutical Excipients , 1994 .

[10]  P Augustijns,et al.  Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  Simon Bates,et al.  Evaluation of Drug-Polymer Miscibility in Amorphous Solid Dispersion Systems , 2009, Pharmaceutical Research.

[12]  J Hadgraft,et al.  Crystallization of hydrocortisone acetate: influence of polymers. , 2001, International journal of pharmaceutics.

[13]  JULIAN F. Johnson,et al.  Mechanical Properties of Polymers: The Influence of Molecular Weight and Molecular Weight Distribution , 1972 .

[14]  Patrick J. Marsac,et al.  Theoretical and Practical Approaches for Prediction of Drug–Polymer Miscibility and Solubility , 2006, Pharmaceutical Research.

[15]  James S. Taylor,et al.  Ideal copolymers and the second‐order transitions of synthetic rubbers. i. non‐crystalline copolymers , 2007 .

[16]  Thomas Rades,et al.  Emerging trends in the stabilization of amorphous drugs. , 2013, International journal of pharmaceutics.

[17]  Peter York,et al.  Mechanisms of dissolution of frusemide pvp solid dispersions , 1987 .

[18]  S. Thakral,et al.  Prediction of drug-polymer miscibility through the use of solubility parameter based Flory-Huggins interaction parameter and the experimental validation: PEG as model polymer. , 2013, Journal of pharmaceutical sciences.

[19]  J. Torrado,et al.  Preparation, dissolution and characterization of albendazole solid dispersions , 1996 .

[20]  Wagh Vinod Tukaram.  Solid Dispersions as Strategy to Improve Oral Bioavailability of Poor Water Soluble Drugs , 2013 .

[21]  A. Ravve,et al.  Principles of Polymer Chemistry , 1995 .

[22]  M. Otsuka,et al.  Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry. , 2001, The Analyst.

[23]  R. Jachowicz.  Dissolution rates of partially water-soluble drugs from solid dispersion systems. I. Prednisolone , 1987 .

[24]  J. Ford.  The current status of solid dispersions. , 1986, Pharmaceutica acta Helvetiae.

[25]  V. Caron,et al.  A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. , 2011, Molecular pharmaceutics.

[26]  Lian Yu,et al.  Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc. , 2010, Journal of pharmaceutical sciences.

[27]  M. Summers,et al.  The effect of wetting agents on the dissolution of indomethacin solid dispersion systems , 1986 .

[28]  Amrit Paudel,et al.  Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in poly(vinylpyrrolidone). , 2010, Molecular pharmaceutics.

[29]  E. Squillante,et al.  Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. , 2004, International journal of pharmaceutics.

[30]  George Zografi,et al.  Physical Properties of Solid Molecular Dispersions of Indomethacin with Poly(vinylpyrrolidone) and Poly(vinylpyrrolidone-co-vinyl-acetate) in Relation to Indomethacin Crystallization , 1999, Pharmaceutical Research.

[31]  Patrick J. Marsac,et al.  Estimation of Drug–Polymer Miscibility and Solubility in Amorphous Solid Dispersions Using Experimentally Determined Interaction Parameters , 2008, Pharmaceutical Research.

[32]  N. Rodríguez-Hornedo,et al.  Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. , 1999, Journal of pharmaceutical sciences.

[33]  T. Rades,et al.  Evaluation of drug-polymer solubility curves through formal statistical analysis: comparison of preparation techniques. , 2015, Journal of pharmaceutical sciences.

[34]  Bruno C. Hancock,et al.  Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. , 1994, Journal of pharmaceutical sciences.

[35]  Feng Qian,et al.  Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development. , 2010, Journal of pharmaceutical sciences.

[36]  N. Lordi,et al.  Thermal Analysis Studies of Glass Dispersion Systems , 1984 .

[37]  W. Higuchi,et al.  Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. , 1969, Journal of pharmaceutical sciences.

[38]  Bruno C. Hancock,et al.  Characteristics and significance of the amorphous state in pharmaceutical systems. , 1997, Journal of pharmaceutical sciences.

[39]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[40]  Patrick Augustijns,et al.  Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30 , 1998 .

[41]  Ravi M Shanker,et al.  Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. , 2010, Journal of pharmaceutical sciences.